References Tesamorelin LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institutes of Health, NIDDK (2018) Tesamorelin (Subcutaneous route) Drug Information Mayo Clinic / IBM Merative (2025) Effects of tesamorelin (TH9507), a growth hormonereleasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials J
Increased heart rate: Small increases in heart rate may be problematic for individuals with heart conditions such as atrial fibrillation or heart failure
Verdict at a Glance Retatrutide demonstrated greater weight loss than survodutide in their respective Phase 2 trials (24.2% vs 18.7%), likely driven by its unique triple-agonist mechanism that adds GIP receptor activation
Yet little is known about what happens when therapy is discontinuedan increasingly important question as real-world discontinuation rates remain high
GLP-1 receptor agonists like semaglutide can enhance the effectiveness of progestins, such as levonorgestrel, which are commonly used in hormonal therapies for endometriosis and endometrial cancer prevention
Most people cant afford that
